Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            TMS

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TMS-007

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: TMS-007

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Biogen

            Deal Size: $353.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition May 12, 2021

            Details:

            Biogen exercised its option to acquire TMS-007, an investigational drug for acute ischemic stroke, from TMS. Biogen’s decision to acquire TMS-007 was based on positive data from a Phase 2a study.